



From Physiologically Based Pharmacokinetic Modeling toward System Biology

Frédéric Y. Bois, Céline Brochot,
Sandrine Micallef, Alexandre Pery.
frederic.bois@ineris.fr

INERIS



Overview

What is a PBPK model?

Main goals of PBPK modelling

Classical PK Data

Inference

Links to Systems Biology

Examples


Current work on cellular stochasticity

- Stochasticity at low exposures
- Analysis at steady state
- Consequences for dose-response curves
- Dynamics

What is missing

What is a PBPK model?

Physiologically-Based Pharmacokinetic model: The body is described as a set of compartments corresponding to organs or tissues where substances can be transported, metabolised, etc.






Main goals of PBPK modelling

- Data integration (QSAR, *in vitro*, *in vivo*, medical imaging)
- Checking complex hypotheses
- Internal dose predictions, exposure dose reconstruction
- Extrapolations
 - Dose
 - Time
 - Administration routes
 - Inter-species
 - Inter-individuals

Classical PK Data

- Times series data, with multilevel structure





Inference

- Inference on parameter values can be made via MCMC in a multilevel Bayesian framework (Gelman *et al.*, JASA, 1996)
- We use Metropolis within Gibbs, Metropolis on the full set of parameters, Metropolis with tempering, Particle algorithms, for :
 - inference
 - posterior predictions, model checking, sensitivity analysis on the structural model
 - optimal design (Amzal *et al.*, JASA, 2006)



Inference

- Inference on parameter values can be made via MCMC in a multilevel Bayesian framework (Gelman *et al.*, JASA, 1996)
- There are typically from 10 to 100 parameters per subject, with 5 to several hundred subjects (Mezzetti *et al.*, JRSS C, 2003)
- Software available
 - PK BUGS
 - MCSim
 - R
 - ACSL




Links to Systems Biology


Links are obvious, as PBPK modelling starts at an upper level of the body hierarchy and progresses downward :

- Metabolic networks (for interactions between multiple chemicals)
- Mechanistic link to effects (perturbation of regulations, signalling,...)
- Impact of stochasticity on activity or damage at the cellular level


Example of PBPK metabolic network



Example of a semi-PBPK detailed reaction path



Current work on cellular stochasticity





- Our PBPK model was implemented in JDesigner 2.0.39 and MCSim 5.0.0. It is parameterised for a human male.
- It has 23 physiological compartments linked through kinetic or transport equations.
- 1,3 butadiene can be eliminated either through expiration or metabolism in the liver (as a 1st order approximation).

Stochasticity at low exposures

- If we consider that a human has typically got 10^{14} cells, the mean cell density in our PBPK model is **$1.34 \cdot 10^{12}$ cells/L**
- According to Higashino *et al.* (2007), exposure to butadiene in general environment in Japan is $0.25 \mu\text{g}/\text{m}^3$. Lifetime excess cancer risk level is estimated at 10^{-5} for exposure concentration $1.7 \mu\text{g}/\text{m}^3$. With a butadiene molar mass of $54.09 \text{ g}/\text{mol}$, 0.25 and $1.7 \mu\text{g}/\text{m}^3$ corresponds to **$2.75 \cdot 10^{12}$** and **$18.7 \cdot 10^{12}$ molecules/L**
- So, we only expect a few molecules per cell at those levels. We adapted our JDesigner model, in terms of flows and volumes, to be able to study cell kinetics.


Analysis at steady state




- Using Dizzy 1.11.4, we simulated for 100 cells the number of molecules per cell at a given time.
- Even at steady state for organ concentration, the concentration per cell can differ substantially between cells.

Consequences for dose-response curves

- Simulated lifetime excess risk cancer due to butadiene metabolites in the liver.
- Assuming a threshold for cellular response.
- Liver response is integrated on all its cells.
 - Plain lines : theoretical dose response with threshold.
 - Diamonds : dose-response obtained from stochastic simulation



Dynamics



- Simulated 9h exposure to $1.7 \mu\text{g}/\text{m}^3$ butadiene and then at $0.25 \mu\text{g}/\text{m}^3$.
- The risk of cancer due to butadiene metabolites in the liver is significantly underestimated by a deterministic estimate of their quantity



What is missing

- We have not linked the posteriors of model parameters to stochastic simulations at the cell level. Let alone the reverse (which might be needed for correct inference
- We have not worked a lot on model structure: structure is quite obvious at the anatomic and physiologic level (huge prior), much less so at the metabolic level.
- We have a software problem, which we might try to solve by adapting our *Mcsim* software